Efficacy of tofacitinib for the treatment of psoriatic arthritis: pooled analysis of two phase 3 studies

Efficacy of tofacitinib for the treatment of psoriatic arthritis: pooled analysis of two phase 3 studies

<strong>Introduction</strong> Tofacitinib is an oral Janus kinase inhibitor for the treatment of psoriatic arthritis (PsA). This post hoc analysis assessed the efficacy of tofacitinib using pooled data from two phase 3 studies of patients with active PsA. <br/><br/> <stron...

Disgrifiad llawn

Manylion Llyfryddiaeth
Prif Awduron:	Nash, P, Coates, L, Fleischmann, R, Papp, K, Gomez-Reino, J, Kanik, K, Wang, C, Wu, J, Menon, S, Hendrikx, T, Ports, W
Fformat:	Journal article
Iaith:	English
Cyhoeddwyd:	Springer Nature 2018

Eitemau Tebyg

Efficacy of Tofacitinib for the Treatment of Psoriatic Arthritis: Pooled Analysis of Two Phase 3 Studies
gan: Peter Nash, et al.
Cyhoeddwyd: (2018-11-01)

Tofacitinib improves composite endpoint measures of disease in patients with psoriatic arthritis
gan: Helliwell, P, et al.
Cyhoeddwyd: (2018)

Safety and efficacy of tofacitinib, an oral janus kinase inhibitor, up to 36 months in patients with active psoriatic arthritis: data from the third interim analysis of opal balance, an open-label, long-term extension study
gan: Nash, P, et al.
Cyhoeddwyd: (2018)

Safety and efficacy of Tofacitinib, an oral Janus Kinase inhibitor, up to 36 Months in patients with active Psoriatic Arthritis: data from the third interim analysis of OPAL balance, an Open-Label, long-term extension study
gan: Nash, P, et al.
Cyhoeddwyd: (2018)

Efficacy of tofacitinib on enthesitis in patients with active psoriatic arthritis: analysis of pooled data from two phase 3 studies
gan: Philip J. Mease, et al.
Cyhoeddwyd: (2023-08-01)

Safety and efficacy of tofacitinib up to 48 months in patients with active psoriatic arthritis: final analysis of the OPAL Balance long-term extension study
gan: Nash, P, et al.
Cyhoeddwyd: (2021)

Impact of baseline body mass index on the efficacy and safety of tofacitinib in patients with psoriatic arthritis
gan: Daniela Graham, et al.
Cyhoeddwyd: (2021-04-01)

Safety and Efficacy of Tofacitinib in Patients with Active Psoriatic Arthritis: Interim Analysis of OPAL Balance, an Open-Label, Long-Term Extension Study
gan: Peter Nash, et al.
Cyhoeddwyd: (2020-06-01)

Tofacitinib as monotherapy following methotrexate withdrawal in patients with psoriatic arthritis previously treated with open-label tofacitinib plus methotrexate: a randomised, placebo-controlled substudy of OPAL Balance
gan: Nash, P, et al.
Cyhoeddwyd: (2020)

Median time to pain improvement in patients with psoriatic arthritis treated with tofacitinib
gan: de Vlam, K, et al.
Cyhoeddwyd: (2018)

Results of studying the clinical efficacy and safety of tofacitinib in the treatment of psoriatic arthritis
gan: T. V. Korotaeva, et al.
Cyhoeddwyd: (2019-05-01)

EFFICACY AND SAFETY OF TOFACITINIB IN PATIENTS WITH PSORIATIC ARTHRITIS IN REAL CLINICAL PRACTICE
gan: E. Yu. Loginova, et al.
Cyhoeddwyd: (2020-06-01)

Psoriatic arthritis - Tofacitinib as a new treatment
gan: Marta Skorupska, et al.
Cyhoeddwyd: (2024-06-01)

Efficacy of tofacitinib in reducing pain in patients with rheumatoid arthritis, psoriatic arthritis or ankylosing spondylitis
gan: Iain B McInnes, et al.
Cyhoeddwyd: (2020-02-01)

Understanding mediators of pain reduction in psoriatic arthritis patients treated with tofacitinib: role of inflammation
gan: Taylor, P, et al.
Cyhoeddwyd: (2019)

The effect of tofacitinib on residual pain in patients with psoriatic arthritis
gan: Dougados, M, et al.
Cyhoeddwyd: (2020)

Network Meta-Analysis of Tofacitinib, Biologic Disease-Modifying Antirheumatic Drugs, and Apremilast for the Treatment of Psoriatic Arthritis
gan: Dafna D. Gladman, MD, et al.
Cyhoeddwyd: (2020-01-01)

Tofacitinib in the management of active psoriatic arthritis: patient selection and perspectives
gan: Ly K, et al.
Cyhoeddwyd: (2019-08-01)

Secukinumab efficacy on resolution of enthesitis in psoriatic arthritis: pooled analysis of two phase 3 studies
gan: Laura C. Coates, et al.
Cyhoeddwyd: (2019-12-01)

Secukinumab efficacy on resolution of enthesitis in psoriatic arthritis: pooled analysis of two phase 3 studies
gan: Coates, L, et al.
Cyhoeddwyd: (2019)

Post-marketing safety surveillance of tofacitinib over 9 years in patients with psoriatic arthritis and rheumatoid arthritis
gan: Burmester, GR, et al.
Cyhoeddwyd: (2023)

Baseline pain severity as a predictor of pain improvement following treatment with tofacitinib in psoriatic arthritis
gan: Ogdie, A, et al.
Cyhoeddwyd: (2018)

Efficacy and safety of tofacitinib in Chinese patients with active psoriatic arthritis: a phase 3, randomised, double-blind, placebo-controlled study
gan: Xiaofeng Zeng, et al.
Cyhoeddwyd: (2023-01-01)

The effect of tofacitinib on residual pain in patients with rheumatoid arthritis and psoriatic arthritis
gan: Dougados, M, et al.
Cyhoeddwyd: (2022)

The effect of tofacitinib on residual pain in patients with rheumatoid arthritis and psoriatic arthritis
gan: Maxime Dougados, et al.
Cyhoeddwyd: (2022-11-01)

Efficacy and Safety of Tofacitinib in Patients with Psoriatic Arthritis or Ankylosing Spondylitis by Cigarette Smoking Status
gan: Alexis Ogdie, et al.
Cyhoeddwyd: (2024-09-01)

Relationships between psoriatic arthritis composite measures of disease activity with patient-reported outcomes in Phase 3 studies of tofacitinib
gan: Coates, L, et al.
Cyhoeddwyd: (2021)

Efficacy and safety of tofacitinib in an open-label, long-term extension study in patients with psoriatic arthritis who received adalimumab or tofacitinib in a Phase 3 randomized controlled study: a post hoc analysis
gan: Dafna D. Gladman, et al.
Cyhoeddwyd: (2024-12-01)

Post-Marketing Safety Surveillance of Tofacitinib over 9 Years in Patients with Psoriatic Arthritis and Rheumatoid Arthritis
gan: Gerd R. Burmester, et al.
Cyhoeddwyd: (2023-07-01)

Adverse events of special interest in clinical trials of rheumatoid arthritis, psoriatic arthritis, ulcerative colitis and psoriasis with 37 066 patient-years of tofacitinib exposure
gan: Peter Nash, et al.
Cyhoeddwyd: (2021-08-01)

Effectiveness of Tofacitinib in Patients Initiating Therapy for Psoriatic Arthritis: Results from the CorEvitas Psoriatic Arthritis/Spondyloarthritis Registry
gan: Philip J. Mease, et al.
Cyhoeddwyd: (2024-01-01)

Comparative efficacy of tofacitinib and adalimumab in patients with psoriatic arthritis in real clinical practice. Data from the Russian nationwide register of patients with psoriatic arthritis
gan: E. Yu. Loginova, et al.
Cyhoeddwyd: (2021-06-01)

Relationships between psoriatic arthritis composite measures of disease activity with patient-reported outcomes in phase 3 studies of tofacitinib
gan: Laura C. Coates, et al.
Cyhoeddwyd: (2021-03-01)

Time to response for clinical and patient-reported outcomes in patients with psoriatic arthritis treated with tofacitinib, adalimumab, or placebo
gan: Gladman, DD, et al.
Cyhoeddwyd: (2022)

Disease-specific composite measures for psoriatic arthritis are highly responsive to a Janus kinase inhibitor treatment that targets multiple domains of disease
gan: Helliwell, P, et al.
Cyhoeddwyd: (2018)

Identifying and quantifying the role of inflammation in pain reduction for patients with psoriatic arthritis treated with tofacitinib: a mediation analysis
gan: de Vlam, K, et al.
Cyhoeddwyd: (2022)

Correction: Post-Marketing Safety Surveillance of Tofacitinib over 9 Years in Patients with Psoriatic Arthritis and Rheumatoid Arthritis
gan: Gerd R. Burmester, et al.
Cyhoeddwyd: (2023-12-01)

Effect of tofacitinib treatment on active MRI sacroiliitis in psoriatic arthritis patients
gan: E. E. Gubar, et al.
Cyhoeddwyd: (2021-05-01)

Median time to pain improvement and the impact of baseline pain severity on pain response in patients with psoriatic arthritis treated with tofacitinib
gan: de Vlam, K, et al.
Cyhoeddwyd: (2021)

Time to response for clinical and patient-reported outcomes in patients with psoriatic arthritis treated with tofacitinib, adalimumab, or placebo
gan: Dafna D. Gladman, et al.
Cyhoeddwyd: (2022-02-01)